May 12th 2017EP. 1: Clinical Pathways in Lung Cancer
May 12th 2017EP. 2: Integrating New Lung Cancer Drugs Into a Formulary
May 12th 2017EP. 3: Molecular Testing in NSCLC and Cost
May 12th 2017EP. 4: Assessing Options in Second-Line NSCLC
May 12th 2017EP. 5: Current Biomarkers in Lung Cancer
May 12th 2017EP. 6: Cost-Benefit Analysis in Lung Cancer
May 12th 2017EP. 7: Outcomes-Based Contracting in Lung Cancer
May 12th 2017EP. 8: Frontline Decision Making in Nondriver Lung Cancer
May 12th 2017EP. 9: Deciding on Second-Line Lung Cancer Therapy
May 12th 2017EP. 10: Role of Immunotherapy in Lung Cancer
May 12th 2017EP. 11: Rationale for Anti-Angiogenesis in Lung Cancer
May 12th 2017EP. 12: Alternative Payment Models and Quality in Lung Cancer
May 12th 2017EP. 13: The REVEL Study in Lung Cancer
May 12th 2017EP. 14: Lung Cancer: Novel Combinations
May 12th 2017EP. 15: Clinical Pathways in NSCLC
May 12th 2017EP. 16: Communicating Policy Changes in Lung Cancer
May 12th 2017EP. 17: Molecular Testing Coverage Decisions in Lung Cancer
May 12th 2017EP. 18: Second-Line NSCLC Coverage Decisions
May 12th 2017EP. 19: Considering Real-World Outcomes in NSCLC
May 12th 2017EP. 20: Incentivizing Quality Care in NSCLC
May 12th 2017EP. 21: Mutation Testing in Nonsquamous NSCLC
May 12th 2017EP. 22: Nondriver NSCLC: Frontline Systemic Therapy
May 12th 2017EP. 23: Maintenance Following Chemotherapy in NSCLC
May 12th 2017EP. 24: NSCLC: Initiating Second-Line Therapy
May 12th 2017EP. 25: Immunotherapy and Chemotherapy in Second-Line NSCLC
May 12th 2017EP. 26: Nondriver NSCLC: Immunotherapy and PD-L1 Expression
May 12th 2017EP. 27: Anti-Angiogenesis in NSCLC
May 12th 2017EP. 28: Sequencing Therapies in NSCLC
